Patents Issued in June 27, 2017
  • Patent number: 9687426
    Abstract: Composition containing an aqueous phase and an emulsifying system, where the emulsifying system contains at least one C10-C30 alkyl phosphate and at least one C8-C24 fatty alkyl ether of polyethylene glycol, the ether comprising from 1 to 19 ethylene glycol units and having an HLB<8 at 25° C. Process for making up or for non-therapeutically caring for keratin fibres, via the application to keratin fibres of the composition. Uses of the composition in particular for obtaining uniform and/or thick makeup on keratin fibres, and as mascara for making up keratin fibres.
    Type: Grant
    Filed: November 5, 2007
    Date of Patent: June 27, 2017
    Assignee: L'OREAL
    Inventors: Olivier Raineau, Isabelle Jacquier
  • Patent number: 9687427
    Abstract: Oral care composition comprises a stannous ion source and a thickener comprising at least 2 agents selected from the group consisting of: i) a linear sulfated polysaccharide; ii) a natural gum; iii) and a non-ionic cellulose derivative. A method for treating the oral cavity comprises administering to the oral cavity the oral care composition.
    Type: Grant
    Filed: February 27, 2015
    Date of Patent: June 27, 2017
    Assignee: The Procter & Gamble Company
    Inventors: Xiaoxiao Li, Yujun Li, Ross Strand, Xiujun Xu
  • Patent number: 9687428
    Abstract: A composition is provided, wherein the composition comprises a water-swellable, water insoluble polymer, a blend of a hydrophilic polymer and a complementary oligomer capable of hydrogen bonding to the hydrophilic polymer, and a whitening agent, preferably a peroxide. The composition finds utility as a tooth whitening composition and is applied to the teeth in need of whitening, and then removed when the degree of whitening has been achieved. In certain embodiments, the composition is translucent. Methods for preparing and using the compositions are also disclosed.
    Type: Grant
    Filed: November 23, 2016
    Date of Patent: June 27, 2017
    Assignees: A. V. TOPCHIEV INSTITUTE OF PETROCHEMICAL SYNTHESIS, RUSSIAN ACADEMY OF SCIENCES, CORIUM INTERNATIONAL, INC.
    Inventors: Parminder Singh, Gary W. Cleary, Sri Mudumba, Mikhail M. Feldstein, Danir F. Bayramov
  • Patent number: 9687429
    Abstract: The present invention relates to a preservative or antimicrobial compositions with broad spectrum antimicrobial activity comprising low concentrations of essential oil (and/or one or more component thereof) and a botanical extract in synergistic combination with a fruit acid and alkanediol, and optionally a solvent. The compositions of the invention may be used in personal care products such as creams or soap products.
    Type: Grant
    Filed: January 26, 2010
    Date of Patent: June 27, 2017
    Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Shanta Modak, Nayana Baiju, Lauserpina Caraos
  • Patent number: 9687430
    Abstract: One aspect of the present invention relates to an effervescent tablet comprising a water-soluble lubricating agent, and a carbonated water cosmetic composition enabled to be used together therewith. One aspect of the present invention relates to an effervescent tablet comprising a crystalline #-hydroxy acid and a water-soluble lubricating agent, and a cosmetic composition using a skin toner for preventing the tablet from floating and allowing the tablet to rapidly form carbon dioxide gas in the cosmetic composition so as to maximize the visual effect and also the effect of carbon dioxide, thereby showing skin whitening, brightening and moisturizing effects and improving the pores.
    Type: Grant
    Filed: March 21, 2014
    Date of Patent: June 27, 2017
    Assignee: AMOREPACIFIC CORPORATION
    Inventors: Ju A Jung, Byung Ryol Paik, Chang Keun Lee, Lee Kyoung Kwon, Joon Ho Bae, Young So Kim
  • Patent number: 9687431
    Abstract: The invention relates to the cosmetic use of isoleucine N-hexadecanoyl of formula (I): CH3—(CH2)14—C(?O)—NH—CH(COOH)—CH(CH3)—CH2—CH3 (I) as a “volumizing” agent and/or as a “plumping” agent for human skin. The invention also relates to a cosmetic treatment method for obtaining a “volumizing” and/or “plumping” effect of the skin of a part of the human body selected from among the breasts, face, cheeks, buttocks and eyelids.
    Type: Grant
    Filed: July 22, 2010
    Date of Patent: June 27, 2017
    Assignee: SOCIETE D'EXPLOITATION DE PRODUITS POUR LES INDUSTRIES CHIMIQUES SEPPIC
    Inventors: Laetitia Cattuzzato, Nathalie Chevrot, Sandy Dumont, Corinne Stoltz
  • Patent number: 9687432
    Abstract: Antimicrobial bispyridine amine compositions that facilitate easy application on the skin, do not penetrate the skin, are compatible with typical deodorant ingredients, and do not cause adverse effects on skin and clothing. In one aspect, the present invention relates to an antimicrobial composition including an organic acid salt of a bispyridine amine where the organic acid contains from about 4 to about 30 carbon atoms. Because the organic acid salts of bispyridine amines are large molecules, they will not easily penetrate the skin, and will stay on the surface where they were applied and where they are needed to have their effect.
    Type: Grant
    Filed: December 23, 2013
    Date of Patent: June 27, 2017
    Assignee: LONZA INC.
    Inventors: James V. Gruber, Diana Ciccognani, Volodymyr B. Pashovych
  • Patent number: 9687433
    Abstract: The present invention is relates to a novel anhydrous dermatological depigmenting compositions comprising a phenolic compound, and methods of making and using the same.
    Type: Grant
    Filed: October 9, 2015
    Date of Patent: June 27, 2017
    Assignee: Ecstasy LLC
    Inventors: Xiaodong Wang, Hua Zhong
  • Patent number: 9687434
    Abstract: The present invention relates to the cosmetic use by external topical route of steviol, of a steviol glycoside derivative or of one of their isomers to stimulate, restore or regulate the metabolism of the cells of the skin.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: June 27, 2017
    Assignee: L'OREAL
    Inventors: Julien Laboureau, Myrian Kauffmann, Yann Mahe
  • Patent number: 9687435
    Abstract: It is intended to provide a liquid oral composition and a liquid food composition in which calcium phosphate such as hydroxyapatite or tricalcium phosphate can be stably dispersed and prevented from being precipitated or separated out even in long-term storage. Calcium phosphate mixed with xanthan gum and polyglycerin fatty acid ester can be stably dispersed even in long-term storage and prevented from being precipitated or separated out even when used in liquid oral compositions such as mouthwashes, liquid dentifrices, and oral detergents or in liquid food compositions such as milk, soy milk, yoghurt, and refreshing beverages. In addition, calcium phosphate mixed with xanthan gum and polyglycerin fatty acid ester further supplemented with an amphoteric surfactant can be more effectively prevented from being precipitated or separated out in liquid oral compositions such as mouthwashes, liquid dentifrices, and oral detergents.
    Type: Grant
    Filed: January 28, 2013
    Date of Patent: June 27, 2017
    Assignee: KABUSHIKI KAISHA SANGI
    Inventors: Keijiro Fujita, Mariko Obuki, Tomoki Saito, Shuji Sakuma
  • Patent number: 9687436
    Abstract: The present invention relates to a nail varnish composition which contains a plasticizer A) and a film-forming agent B), characterized in that the plasticizer A) comprises at least two carbonate structural units of formula (I) and has an average molecular weight of ?450 g/mol, determined by gel permeation chromatography against a polystyrene standard in tetrahydrofurane at 23° according to DIN 55672-1, and a hydroxyl functionality of ?1.5 and ?6. The invention further relates to a coating which can be obtained from the nail varnish composition according to the invention, to a substrate coated with such a coating, and to a cosmetic method for coating finger and/or toe nails, according to which method a nail varnish composition according to the invention is applied to finger and/or toe nails. The invention also relates to the use of compounds as plasticizers in nail varnish compositions which compounds contain specific carbonate structural units.
    Type: Grant
    Filed: September 19, 2014
    Date of Patent: June 27, 2017
    Assignee: Covestro Deutschland AG
    Inventors: Sophie Viala, Sebastian Dorr
  • Patent number: 9687437
    Abstract: Compositions and methods are disclosed for preventing or reducing frizzy appearance of keratin fibers, including hair, and reducing the amount of fly-away strands of hair, particularly in humid conditions, by forming a coating on hair that is resistant to water vapors from the air or surrounding environment. The compositions comprise a combination of a hydrophobic particulate material comprising a hydrophobically surface-modified aluminum oxide and one or more hydrophobic film formers in a cosmetically acceptable vehicle.
    Type: Grant
    Filed: December 4, 2014
    Date of Patent: June 27, 2017
    Assignee: Avon Products, Inc
    Inventors: Mark S. Garrison, Freda E. Robinson, Giovana A. Sandstrom, Kenneth A. Buckridge, Sen Yang, Xiaochun Luo
  • Patent number: 9687438
    Abstract: Provided is a method for enhancing collagen secretion and preventing cutaneous aging using Chenopodium formosanum extract. The Chenopodium formosanum extract includes active ingredients that are able to effectively enhance the ability of collagen secretion of dermal fibroblasts as well as prevent the glycation of collagen and resist the damage of ultraviolet light exposure. The preparation of the Chenopodium formosanum extract is environmental friendly and is able to promote the economic value of Chenopodium formosanum; thus, the present invention is suitable for applications in the development of food products, especially beverages, skin care and cosmetic products.
    Type: Grant
    Filed: March 3, 2015
    Date of Patent: June 27, 2017
    Assignee: TCI Co., Ltd.
    Inventors: Hsiang-Ling Su, Chin-Hsiu Yu, Ying-Ju Chen
  • Patent number: 9687439
    Abstract: A composition comprising an extract from damaged plant parts from the Moringaceae genus, at least one oligopeptide, at least one extract from the Laminaria genus, and whey protein and a method for stimulating collagen synthesis in skin cells.
    Type: Grant
    Filed: January 21, 2016
    Date of Patent: June 27, 2017
    Assignee: ELC Management LLC
    Inventors: Nadine Pernodet, Krystle Corallo, Dawn Layman, Donald Collins
  • Patent number: 9687440
    Abstract: Compositions comprising at least one ingredient that stimulates, enhances, or increases CGRP expression, and a physiologically- or cosmetically-acceptable vehicle. The ingredient may be a compound, natural ingredient, such as a plant or fungus, derivatives, analogs, mimetics, synthetics and the like that stimulates CGRP expression. The CGRP plant includes plants, plant materials, plant extracts, synthetics, or combinations thereof that stimulate CGRP expression. The disclosure is also directed to methods of using the CGRP compositions for decreasing, reducing, or inhibiting fine lines or wrinkled skin.
    Type: Grant
    Filed: March 26, 2015
    Date of Patent: June 27, 2017
    Assignee: Avon Products, Inc
    Inventors: John W. Lyga, Laurence Dryer
  • Patent number: 9687441
    Abstract: Compositions for lubricating skin during application of a fascia tissue treatment device, thereby reducing the appearance of cellulite in skin and methods of forming such compositions.
    Type: Grant
    Filed: June 14, 2016
    Date of Patent: June 27, 2017
    Assignee: Ashley Diana Black International Holdings, LLC
    Inventor: Ashley D. Black
  • Patent number: 9687442
    Abstract: The present invention relates generally to methods and compositions useful for application to skin and hair comprising hydrolyzed algae extract, saccharide isomerate, and a dermatologically acceptable vehicle wherein the composition or method is capable of moisturizing and/or improving the appearance and/or condition of skin and/or hair.
    Type: Grant
    Filed: July 25, 2016
    Date of Patent: June 27, 2017
    Assignee: Mary Kay Inc.
    Inventors: Tiffany Carle, Bob Foley, Julia Collier, Wanli Zhao, Geetha Kalahasti
  • Patent number: 9687443
    Abstract: Compositions useful for improving effectiveness of alpha-2-adrenergic agonist components include carrier components, alpha-2-adrenergic agonist components, solubility enhancing components which aid in solubilizing the alpha-2-adrenergic agonist components. In one embodiment, the alpha-2-adrenergic agonist components include alpha-2-adrenergic agonists. In another embodiment, the solubility enhancing components include carboxymethylcellulose.
    Type: Grant
    Filed: February 19, 2016
    Date of Patent: June 27, 2017
    Assignee: ALLERGAN, INC.
    Inventors: Richard Graham, Peter Bakhit, Orest Olejnik
  • Patent number: 9687444
    Abstract: The present invention, as described above and as further defined by the claims, provides methods of administering an active agent via adhesion of a film to a mucous membrane in the oral cavity of a mammal, as well as and ODF formed therefore. An active agent may be ingested as the ODF dissolves resulting in systemic treatment of the mammal. In additional embodiments, an ODF may provide topical administration of an active agent.
    Type: Grant
    Filed: March 28, 2014
    Date of Patent: June 27, 2017
    Inventor: Andrew L. Skigen
  • Patent number: 9687445
    Abstract: A control release and abuse-resistant opiate drug delivery oral wafer or edible oral film dosage to treat pain and substance abuse is provided. The drug delivery oral wafer or edible oral film dosage includes a controlled release layer containing enteric-release beads dispersed in a polymer matrix. The enteric-release beads are formed from a therapeutic amount of an opioid agonist and/or pharmaceutically acceptable salt thereof and a sub-therapeutic amount of opioid antagonist and/or pharmaceutically acceptable salt thereof coated or encapsulated in an enteric-release polymer. The controlled release polymer matrix dissolves or disintegrates following administration or consumption of the oral wafer or edible oral film, releasing the enteric-release beads to be swallowed, with subsequent absorption of the active ingredients within the patient's intestines.
    Type: Grant
    Filed: April 12, 2012
    Date of Patent: June 27, 2017
    Assignee: LTS Lohmann Therapie-Systeme AG
    Inventor: Michael Hsin Chwen Li
  • Patent number: 9687446
    Abstract: The present invention is drawn to methods of preparing a bioactive agent-containing emulsion for delivery to a biological system. This method can comprise the step of jetting a bioactive agent and a first fluid medium from a fluid-jet pen into a second fluid medium to form a bioactive agent-containing emulsion, wherein the second fluid comprises a continuous phase of the emulsion. Alternatively, a method of preparing a bioactive agent-containing liposome can comprise jetting a lipid-containing composition and a bioactive agent from a fluid-jet pen into a medium to form a bioactive agent-containing liposome carried by the medium. The present invention is also drawn to fluid-jet pens and systems configured for making liposome- and emulsion-containing biological agents.
    Type: Grant
    Filed: August 31, 2009
    Date of Patent: June 27, 2017
    Assignee: Hewlett-Packard Development Company, L.P.
    Inventors: John Stephen Dunfield, James W. Ayres
  • Patent number: 9687447
    Abstract: The present invention relates to method for preparing liposome-based constructs comprising a peptide, particularly an antigenic peptide, of interest modified through hydrophobic moieties reconstituted in liposomes and to the antigenic constructs obtained with said method. The invention further relates to the use of said constructs for the therapeutic and diagnostic use in the treatment of diseases and disorders, which are caused by or associated with proteopathy such as Alzheimer's Disease.
    Type: Grant
    Filed: October 26, 2011
    Date of Patent: June 27, 2017
    Assignee: AC Immune S.A.
    Inventors: Pedro Reis, David Hickman, Maria Pihlgren Bosch, Andreas Muhs, Andrea Pfeifer
  • Patent number: 9687448
    Abstract: The present invention relates to lipid nanoparticles containing a biodegradable cationic lipid which provide improved delivery of active pharmaceutical ingredients, such as siRNA.
    Type: Grant
    Filed: December 4, 2013
    Date of Patent: June 27, 2017
    Assignee: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Akin Akinc, Martin Maier, Varun Kumar
  • Patent number: 9687449
    Abstract: A delivery vehicle for bioactive agents and live probiotic microbes to aquatic animals protects the bioactive compounds and microbes from digestion and destruction in the animal stomach. It provides for controlled release of bioactive agents and live probiotic microbes to aquatic animals in the form of dry or wet beadlets with essential nutrients and attractants bound with soluble starch and cross-linked alginate. The bioactive agents and live probiotic microbes can be bound with emulsified high-amylose starch and embedded in the beadlets in the form of microparticles.
    Type: Grant
    Filed: November 6, 2003
    Date of Patent: June 27, 2017
    Assignee: Advanced Bionutrition Corp.
    Inventor: Moti Harel
  • Patent number: 9687450
    Abstract: A process for forming microspheres is disclosed. The process includes contacting a solvent with a modified cellulose to form a solution; contacting the modified cellulose solution with at least one bioactive agent to form a discontinuous phase liquid; contacting the discontinuous phase liquid with a continuous phase liquid to form an emulsion; and contacting the emulsion with a third phase liquid to extract the solvent from the emulsion, thereby forming a plurality of modified cellulose microspheres.
    Type: Grant
    Filed: February 26, 2016
    Date of Patent: June 27, 2017
    Assignee: Covidien LP
    Inventors: Phillip Blaskovich, Valentino Tramontano, Joshua Kennedy, Rachit Ohri
  • Patent number: 9687451
    Abstract: A compressed tablet of a pharmaceutical compound which contains uncoated pellets containing a pharmaceutical compound, where the uncoated pellets are dispersed in a matrix containing the pellets and a swellable polymer.
    Type: Grant
    Filed: March 22, 2010
    Date of Patent: June 27, 2017
    Assignee: GLATT AIR TECHNIQUES, INC.
    Inventors: Orapin P. Rubino, David M. Jones
  • Patent number: 9687452
    Abstract: This invention relates to coated digestive enzyme preparations and enzyme delivery systems and pharmaceutical compositions comprising the preparations. This invention further relates to methods of preparation and use of the systems, pharmaceutical compositions and preparations to treat persons having ADD, ADHD, autism, cystic fibrosis and other behavioral and neurological disorders.
    Type: Grant
    Filed: April 22, 2015
    Date of Patent: June 27, 2017
    Assignee: Curemark, LLC
    Inventors: Joan M. Fallon, Matthew Heil
  • Patent number: 9687453
    Abstract: [Problem] To provide a novel pharmaceutical composition which contains a medically active component and which can suppress delays in the release of said component due to gelling. [Solution] This solid pharmaceutical composition contains a compound represented by general formula (1), or a salt thereof, a cellulosic excipient, and a salting-out agent.
    Type: Grant
    Filed: April 24, 2014
    Date of Patent: June 27, 2017
    Assignee: KYORIN PHARMACEUTICAL CO., LTD.
    Inventors: Hiroshi Uchida, Masataka Hanada, Yoshikazu Miyazaki
  • Patent number: 9687454
    Abstract: The present invention relates to products and methods for treatment of narcotic dependence in a user. The invention more particularly relates to self-supporting dosage forms which provide an active agent for treating narcotic dependence while providing sufficient buccal adhesion of the dosage form.
    Type: Grant
    Filed: January 6, 2016
    Date of Patent: June 27, 2017
    Assignee: Indivior UK Limited
    Inventors: Garry L. Myers, Samuel D. Hilbert, Bill J. Boone, Beuford Arlie Bogue, Pradeep Sanghvi, Madhusudan Hariharan
  • Patent number: 9687455
    Abstract: Contained herein are compositions, formulations, methods, and kits for treating regional fat deposits and fat-related conditions. Certain methods comprise administering tetradecyl sulfate, tetradecyl sulfate-like compounds, and pharmaceutically or cosmetically acceptable salts, solvates, prodrugs, or esters thereof and a liquid carrier.
    Type: Grant
    Filed: August 14, 2015
    Date of Patent: June 27, 2017
    Inventor: John Daniel Dobak
  • Patent number: 9687456
    Abstract: Nutritional compositions and methods of making and using the nutritional compositions are provided. In a general embodiment, a nutritional composition includes exogenous vitamin K2. The nutritional compositions may further include an additional component selected from the group consisting of phosphorus, magnesium, zinc, iron, copper, manganese, calcium, vitamin D, osteopontin and combinations thereof.
    Type: Grant
    Filed: April 14, 2016
    Date of Patent: June 27, 2017
    Assignee: Nestec S.A.
    Inventors: Douglas Richard Bolster, Zamzam Kabiry Roughead
  • Patent number: 9687457
    Abstract: Problem to be Solved by the Invention: To providing a method for ameliorating DHIC. Means for Solving the Problem: This invention is directed to a treating method for DHIC, comprising the step of administering a therapeutically effective amount of 3-(15-hydroxypentadecyl)-2,4,4-trimethyl-2-cyclohexene-1-one, a salt thereof, or a solvate thereof.
    Type: Grant
    Filed: May 16, 2016
    Date of Patent: June 27, 2017
    Assignee: Taiho Pharmaceutical Co., Ltd.
    Inventors: Yukio Hayashi, Takahisa Noma
  • Patent number: 9687458
    Abstract: The present invention relates to the administration of compositions comprising an antiestrogen, preferably a selective estrogen receptor modulator (SERM) such as trans-clomiphene, for treating cancer and associated diseases. The invention is also directed to methods for reducing IGF-1 levels in a subject in need thereof by administering a composition comprising an antiestrogen, preferably a SERM such as trans-clomiphene.
    Type: Grant
    Filed: October 22, 2013
    Date of Patent: June 27, 2017
    Assignee: Repros Therapeutics Inc.
    Inventors: Joseph S. Podolski, Ronald D. Wiehle, Kuang Hsu, Greg Fontenot
  • Patent number: 9687459
    Abstract: The present inventions concerns derivatives of aminocyclobutane, particularly as NMDA receptor antagonists, their application in human therapy and their method of preparation. These compounds correspond to the general formula (1): wherein: X1 represents a hydrogen atom or fluorine atom; X2 is a hydrogen atom or fluorine atom or chlorine atom; R1 represents a hydrogen atom or fluorine atom or chlorine atom or methyl group or methoxy group or cyano group; R2 represents independently or together a methyl group or ethyl group.
    Type: Grant
    Filed: September 12, 2016
    Date of Patent: June 27, 2017
    Assignee: PIERRE FABRE MEDICAMENT
    Inventors: Bernard Vacher, Elodie Blanc, Ronan Depoortere
  • Patent number: 9687460
    Abstract: This invention provides a method of enhancing NMDAR-mediated neurotransmission in a disease associated with NMDAR antibody production, said method comprising administering an NMDAR agonist, an alanine-serine-cysteine transporter inhibitor, a D-amino acid oxidase inhibitor, a glycine transport inhibitor or a combination thereof to said subject. This invention also provides a method of mitigating the severity of, mitigating the pathogenesis of, lowering the incidence of or treating a disease associated with NMDAR antibody production, said method comprising administering an agent, which is an NMDAR agonist, an alanine-serine-cysteine transporter inhibitor, a D-amino acid oxidase inhibitor, a glycine transport inhibitor or a combination thereof to said subject.
    Type: Grant
    Filed: May 26, 2014
    Date of Patent: June 27, 2017
    Assignee: SARAH HERZOG MEMORIAL HOSPITAL-EZRATH NASHIM
    Inventor: Uriel Heresco-Levy
  • Patent number: 9687461
    Abstract: Methods for detecting risks for and/or causes of metabolic syndrome or hyperferritinemia in accordance with several embodiments can include the step of measuring the level of heptadecanoic acid in a blood sample of a subject. The methods of several embodiments can further include the step of deeming the subject as having or being at risk of metabolic syndrome if the amount of heptadecanoic acid is below 0.4% of all fatty acids in the sera or plasma. The methods for treating metabolic syndrome or hyperferritinemia according to several embodiments can also include the step of administering a daily dose of heptadecanoic acid to a subject suffering from metabolic syndrome or hyperferritinemia for a period of time from three weeks to twenty-four weeks, wherein the minimum daily dose comprises about 3 mg per lb (or 6 mg per kg) of body weight.
    Type: Grant
    Filed: December 28, 2015
    Date of Patent: June 27, 2017
    Assignee: The United States of America, as Represented by the Secretary of the Navy
    Inventor: Stephanie Venn-Watson
  • Patent number: 9687462
    Abstract: The present invention relates generally to the field of lipids and in particular aims at improving lipid absorption, for example under conditions of lipid maldigestion or malabsorption. One embodiment of the present invention relates to a composition comprising a sn-2 monoacylglycerol derivative, wherein the sn-1 and sn-3 positions are blocked by protective groups. The acyl group may be a fatty acid, for example one with anti-inflammatory properties.
    Type: Grant
    Filed: November 10, 2016
    Date of Patent: June 27, 2017
    Assignees: Nestec S.A., Beth Israel Deaconess Medical Center, Inc.
    Inventors: Bruce Bistrian, Frederic Destaillats, Cristina Cruz-Hernandez, Fabiola Dionisi, Isabelle Masserey-Elmelegy, Manuel Oliveira, Julie Celine Moulin
  • Patent number: 9687463
    Abstract: A method for treating eczema including the steps of applying an isothiocyanate functional surfactant to an area affected by eczema, wherein the isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant.
    Type: Grant
    Filed: September 29, 2015
    Date of Patent: June 27, 2017
    Assignee: The William M. Yarbrough Foundation
    Inventor: Michael E. Silver
  • Patent number: 9687464
    Abstract: There is provided a conjugate of a delivery agent containing a chemical moiety and at least one flavonoid. The flavonoid exists in a monomeric form or dimeric form before conjugation and remains in the monomeric form or dimeric form after conjugation. Preferably, the conjugate comprises two flavonoids. The delivery agent is conjugated at the C6 and/or the C8 position of the A ring of the flavonoid. An anti-cancer agent delivery vehicle comprising an anti-cancer agent and the conjugate is also provided.
    Type: Grant
    Filed: March 11, 2011
    Date of Patent: June 27, 2017
    Assignee: Agency for Science, Technology and Research
    Inventors: Motoichi Kurisawa, Kun Liang, Susi Tan, Joo Eun Chung, Jackie Y. Ying
  • Patent number: 9687465
    Abstract: The present invention relates to pharmaceutical compositions for topical use (including also dermatological compositions), for treating skin conditions and afflictions, such as rosacea and symptoms and conditions associated there from.
    Type: Grant
    Filed: November 27, 2012
    Date of Patent: June 27, 2017
    Assignee: SOL-GEL TECHNOLOGIES LTD.
    Inventors: Hanan Sertchook, Ofer Toledano, Haim Bar-Simantov
  • Patent number: 9687466
    Abstract: The use of dianhydrogalactitol provides a novel therapeutic modality for the treatment of glioblastoma multiforme. Dianhydrogalactitol acts as an alkylating agent on DNA that creates N7 methylation. Dianhydrogalactitol is effective in suppressing the growth of cancer stem cells and is active against tumors that are refractory to temozolomide; the drug acts independently of the MGMT repair mechanism.
    Type: Grant
    Filed: April 4, 2014
    Date of Patent: June 27, 2017
    Assignee: DELMAR PHARMACEUTICALS, INC.
    Inventors: Jeffrey A. Bacha, Dennis Brown, Sandra Dunn, Anne Steinø
  • Patent number: 9687467
    Abstract: Provided herein are methods and assays relating to the diagnosis and treatment of a taxane-resistant cancer. Such methods and assays comprise determining the level of expression of miR-135a in a biological sample from a subject having or suspected of having a taxane-resistant cancer or from a subject that was or is being treated with a taxane anti-cancer agent. Also provided herein are methods for treating such cancers by administering an inhibitor of the miR-135a pathway and a taxane to a subject in need thereof.
    Type: Grant
    Filed: April 4, 2012
    Date of Patent: June 27, 2017
    Assignee: Children's Medical Center Corporation
    Inventors: Bruce R. Zetter, Amy Holleman, Ivy Chung
  • Patent number: 9687468
    Abstract: The present invention relates to the preparation of Cynara scolymus leaf extracts, which are useful for the prevention and treatment of dyslipidaemia, in particular to increase HDL cholesterol in patients at cardiovascular risk. Said extracts are useful to normalize the lipid and carbohydrate balances and significantly increase the value of HDL cholesterol by favorably changing the LDL/HDL ratio, especially in post-infarction patients with drug-induced dyslipidaemia.
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: June 27, 2017
    Assignee: INDENA S.P.A.
    Inventor: Ezio Bombardelli
  • Patent number: 9687469
    Abstract: A pharmaceutical composition for the prevention and treatment of cancer with specific flavanoid-based compounds selected from among the groups of Flavone, Flavanone and Flavanol, a method for the prevention and treatment of cancer and inflammation using the specific flavonoid-based pharmaceutical compositions, a method for isolating the flavonoid-based pharmaceutical compositions from raw plant material, and a method for synthesizing said specific flavonoid-based pharmaceutical compositions.
    Type: Grant
    Filed: August 25, 2015
    Date of Patent: June 27, 2017
    Assignees: University of Maryland, Baltimore, Educational & Scientific LLC
    Inventors: Henry Lowe, Ngeh J. Toyang, Joseph Bryant
  • Patent number: 9687470
    Abstract: A method for the prevention of filariasis includes administering to a subject a therapeutically effective amount of a compound of the general formula (1) or at least one of racemates, enantiomers, diastereomers, solvates, hydrates, pharmaceutically acceptable salts, and esters of general formula (1), wherein, R is selected from the group comprising n-propyl, n-butyl, and at least one of structural elements (2a), (2b), (3a), (3b), (4), (5), (6a), (6b), (7a), and (7b):
    Type: Grant
    Filed: March 16, 2015
    Date of Patent: June 27, 2017
    Assignee: RHEINISCHE FRIEDRICH-WILHELMS UNIVERSITAET BONN
    Inventors: Kenneth Michael Pfarr, Achim Hoerauf, Gabriele Maria Koenig, Sabine Specht, Andrea Schiefer, Till Friedrich Schaeberle, Alexander Schmitz, Stefan Kehraus
  • Patent number: 9687471
    Abstract: This invention relates to improved solutions comprising ascorbic acid (vitamin C). These solutions may comprise as much as 15% ascorbic acid; they are stable for at least two years, without no significant development of yellowish coloration and no substantial (not more than 10%) degradation of the vitamin. The process involves sequential additions of ascorbic acid and ethoxydiglycol to a first solution of vitamin in water, which are followed by addition of propylene glycol. The stirring speed that occurs during the additions favors a process of micronization. Mild heating is used to achieve ascorbic acid concentrations equivalent to about 6% in 10% water or higher.
    Type: Grant
    Filed: January 29, 2014
    Date of Patent: June 27, 2017
    Assignee: VIVIER CANADA INC.
    Inventors: Ghislain Vivier, Anthony Costa
  • Patent number: 9687472
    Abstract: The current application teaches methods and compositions useful for the treatment of cancer through administration of an antioxidant together with an immune stimulator at concentrations sufficient to augment antitumor immunity while simultaneously preventing inhibition of T cell function as a result of tumor secreted oxidative stress. Compositions such as toll like receptor agonists in combination with antioxidants are disclosed. In further embodiments, the application teaches the use of antioxidants to prevent immunotherapy associated oxidative stress, of which, one manifestation is vascular leak syndrome. In one specific embodiment, the application teaches the use of intravenous ascorbic acid as a means of reducing IL-2 associated toxicity.
    Type: Grant
    Filed: May 7, 2015
    Date of Patent: June 27, 2017
    Assignee: Batu Biologics
    Inventors: Samuel C. Wagner, Andy J. Kim, Dimitri N. Theofilopoulos, Brandon R. Dolan, Naseem Ajili
  • Patent number: 9687473
    Abstract: The present invention describes methods of treating dementia comprising administering an effective daily dose of N-[2-(6-fluoro-1H-indol-3-yl)ethyl]-3-(2,2,3,3-tetrafluoropropoxy)benzylamine to improve or augment the effect of an acetylcholinesterase inhibitor.
    Type: Grant
    Filed: March 30, 2016
    Date of Patent: June 27, 2017
    Assignee: H. LUNDBECK A/S
    Inventors: Ellen Schmidt, Johan Areberg
  • Patent number: 9687474
    Abstract: In a patch comprising a support layer and an adhesive agent layer, the adhesive agent layer comprises asenapine and/or a pharmaceutically acceptable salt thereof, isopropyl palmitate, and an adhesive base agent.
    Type: Grant
    Filed: July 25, 2013
    Date of Patent: June 27, 2017
    Assignee: HISAMITSU PHARMACEUTICAL CO., INC.
    Inventors: Masayuki Suzuki, Hiroaki Okutsu, Takashi Yasukochi, Yasunori Takada
  • Patent number: 9687475
    Abstract: The present invention provides extended release pharmaceutical formulations of valsartan with controlled impurity levels. Particularly, the present invention provides extended release valsartan formulation which is substantially free of valsartan R-isomer impurity.
    Type: Grant
    Filed: March 24, 2016
    Date of Patent: June 27, 2017
    Assignees: Ezra Pharma LLC, Rubicon Research Private Limited
    Inventors: Joseph A. Fix, Shirish A. Shah, Pratibha S. Pilgaonkar, Anilkumar S. Gandhi